Family · Pharmaceutical analytical standards
Rivaroxaban
The first oral direct factor Xa inhibitor, approved in Europe in 2008. It prevents thrombosis and stroke without the frequent clotting tests required by older anticoagulants. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?The -xaban ending shared by its whole class (rivaroxaban, apixaban, edoxaban) names the target itself: factor Xa.
No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
